|
1
|
Kgatle MM, Kalla AA, Islam MM, Sathekge M
and Moorad R: Prostate cancer: Epigenetic alterations, risk
factors, and therapy. Prostate Cancer. 2016:56538622016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liu C, Zhu Y, Lou W, Nadiminty N, Chen X,
Zhou Q, Shi XB, deVere White RW and Gao AC: Functional p53
determines docetaxel sensitivity in prostate cancer cells.
Prostate. 73:418–427. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Grasso CS, Wu YM, Robinson DR, Cao X,
Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC,
et al: The mutational landscape of lethal castration-resistant
prostate cancer. Nature. 487:239–243. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Traish AM and Morgentaler A: Epidermal
growth factor receptor expression escapes androgen regulation in
prostate cancer: A potential molecular switch for tumour growth. Br
J Cancer. 101:1949–1956. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kambhampati S, Ray G, Sengupta K, Reddy
VP, Banerjee SK and Van Veldhuizen PJ: Growth factors involved in
prostate carcinogenesis. Front Biosci. 10:1355–1367. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tzouvelekis A, Ntolios P, Karameris A,
Vilaras G, Boglou P, Koulelidis A, Archontogeorgis K, Kaltsas K,
Zacharis G, Sarikloglou E, et al: Increased expression of epidermal
growth factor receptor (EGF-R) in patients with different forms of
lung fibrosis. Biomed Res Int. 2013:6543542013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu YH, Wei XL, Hu GQ and Wang TX:
Quinolone-indolone conjugate induces apoptosis by inhibiting the
EGFR-STAT3-HK2 pathway in human cancer cells. Mol Med Rep.
12:2749–2756. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wee P and Wang Z: Epidermal growth factor
receptor cell proliferation signaling pathways. Cancers (Basel).
9:522017. View Article : Google Scholar
|
|
9
|
Weerasinghe P, Garcia GE, Zhu Q, Yuan P,
Feng L, Mao L and Jing N: Inhibition of Stat3 activation and tumor
growth suppression of non-small cell lung cancer by G-quartet
oligonucleotides. Int J Oncol. 31:129–136. 2007.PubMed/NCBI
|
|
10
|
Zhang X, Yue P, Page BD, Li T, Zhao W,
Namanja AT, Paladino D, Zhao J, Chen Y, Gunning PT and Turkson J:
Orally bioavailable small-molecule inhibitor of transcription
factor Stat3 regresses human breast and lung cancer xenografts.
Proc Natl Acad Sci USA. 109:9623–9628. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tai WT, Cheng AL, Shiau CW, Huang HP,
Huang JW, Chen PJ and Chen KF: Signal transducer and activator of
transcription 3 is a major kinase-independent target of sorafenib
in hepatocellular carcinoma. J Hepatol. 55:1041–1048. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kortylewski M and Yu H: Stat3 as a
potential target for cancer immunotherapy. J Immunother.
30:131–139. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Su JC, Lin KL, Chien CM, Chuang PW, Chang
LS and Lin SR: Concomitant inactivation of the epidermal growth
factor receptor, phosphatidylinositol 3-kinase/Akt and Janus
tyrosine kinase 2/signal transducer and activator of transcription
3 signalling pathways in cardiotoxin III-treated A549 cells. Clin
Exp Pharmacol Physiol. 37:833–840. 2010.PubMed/NCBI
|
|
14
|
Minucci S and Pelicci PG: Histone
deacetylase inhibitors and the promise of epigenetic (and more)
treatments for cancer. Nat Rev Cancer. 6:38–51. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Reichert N, Choukrallah MA and Matthias P:
Multiple roles of class I HDACs in proliferation, differentiation,
and development. Cell Mol Life Sci. 69:2173–2187. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kwiecińska P, Wróbel A, Taubøll E and
Gregoraszczuk EŁ: Valproic acid, but not levetiracetam, selectively
decreases HDAC7 and HDAC2 expression in human ovarian cancer cells.
Toxicol Lett. 224:225–232. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Weichert W, Röske A, Gekeler V, Beckers T,
Stephan C, Jung K, Fritzsche FR, Niesporek S, Denkert C, Dietel M
and Kristiansen G: Histone deacetylases 1, 2 and 3 are highly
expressed in prostate cancer and HDAC2 expression is associated
with shorter PSA relapse time after radical prostatectomy. Br J
Cancer. 98:604–610. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sun S, Han Y, Liu J, Fang Y, Tian Y, Zhou
J, Ma D and Wu P: Trichostatin A targets the mitochondrial
respiratory chain, increasing mitochondrial reactive oxygen species
production to trigger apoptosis in human breast cancer cells. PLoS
One. 9:e916102014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Watson JA, McKenna DJ, Maxwell P, Diamond
J, Arthur K, McKelvey-Martin VJ and Hamilton PW: Hyperacetylation
in prostate cancer induces cell cycle aberrations, chromatin
reorganization and altered gene expression profiles. J Cell Mol
Med. 14:1668–1682. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ma J, Guo X, Zhang S, Liu H, Lu J, Dong Z,
Liu K and Ming L: Trichostatin A, a histone deacetylase inhibitor,
suppresses proliferation and promotes apoptosis of esophageal
squamous cell lines. Mol Med Rep. 11:4525–4531. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang Y, Xu Q, Liu G, Huang H, Lin W,
Huang Y, Chi Z, Chen S, Lan K, Lin J and Zhang Y: Effect of histone
deacetylase on prostate carcinoma. Int J Clin Exp Pathol.
8:15030–15034. 2015.PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gan Y, Shi C, Inge L, Hibner M, Balducci J
and Huang Y: Differential roles of ERK and Akt pathways in
regulation of EGFR-mediated signaling and motility in prostate
cancer cells. Oncogene. 29:4947–4958. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bruzzese F, Leone A, Rocco M, Carbone C,
Piro G, Caraglia M, Di Gennaro E and Budillon A: HDAC inhibitor
vorinostat enhances the antitumor effect of gefitinib in squamous
cell carcinoma of head and neck by modulating ErbB receptor
expression and reverting EMT. J Cell Physiol. 226:2378–2390. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
You BR and Park WH: Trichostatin A induces
apoptotic cell death of HeLa cells in a Bcl-2 and oxidative
stress-dependent manner. Int J Oncol. 42:359–366. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Frew AJ, Johnstone RW and Bolden JE:
Enhancing the apoptotic and therapeutic effects of HDAC inhibitors.
Cancer Lett. 280:125–133. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Emanuele S, Lauricella M, Carlisi D,
Vassallo B, D'Anneo A, Di Fazio P, Vento R and Tesoriere G: SAHA
induces apoptosis in hepatoma cells and synergistically interacts
with the proteasome inhibitor Bortezomib. Apoptosis. 12:1327–1338.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chou CW, Wu MS, Huang WC and Chen CC: HDAC
inhibition decreases the expression of EGFR in colorectal cancer
cells. PLoS One. 6:e180872011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
LaBonte MJ, Wilson PM, Fazzone W, Russell
J, Louie SG, El-Khoueiry A, Lenz HJ and Ladner RD: The dual
EGFR/HER2 inhibitor lapatinib synergistically enhances the
antitumor activity of the histone deacetylase inhibitor
panobinostat in colorectal cancer models. Cancer Res. 71:3635–3648.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yokoyama S, Feige E, Poling LL, Levy C,
Widlund HR, Khaled M, Kung AL and Fisher DE: Pharmacologic
suppression of MITF expression via HDAC inhibitors in the
melanocyte lineage. Pigment Cell Melanoma Res. 21:457–463. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kiliccioglu I, Konac E, Varol N, Gurocak S
and Yucel Bilen C: Apoptotic effects of proteasome and histone
deacetylase inhibitors in prostate cancer cell lines. Genet Mol
Res. 13:3721–3731. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lou Y, Wang Z, Xu Y, Zhou P, Cao J, Li Y,
Chen Y, Sun J and Fu L: Resveratrol prevents doxorubicin-induced
cardiotoxicity in H9c2 cells through the inhibition of endoplasmic
reticulum stress and the activation of the Sirt1 pathway. Int J Mol
Med. 36:873–880. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Menna P, Paz OG, Chello M, Covino E,
Salvatorelli E and Minotti G: Anthracycline cardiotoxicity. Expert
Opin Drug Saf. 11 (Suppl 1):S21–S36. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang X, Xu J, Wang H, Wu L, Yuan W, Du J
and Cai S: Trichostatin A, a histone deacetylase inhibitor,
reverses epithelial-mesenchymal transition in colorectal cancer
SW480 and prostate cancer PC3 cells. Biochem Biophys Res Commun.
456:320–326. 2015. View Article : Google Scholar : PubMed/NCBI
|
